• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Guidance Offers Recommendations for PRO Assessments in COVID-19 Trials

FDA Guidance Offers Recommendations for PRO Assessments in COVID-19 Trials

September 21, 2020

COVID-19 outpatient treatment and prevention trials can use a new 14-point symptom scale for assessing patient reported outcomes (PRO), according to a direct-to-final guidance the FDA released last week.

In addition to the symptom-reporting scale, FDA recommendations for systematic evaluation of outcomes include conducting assessments daily and at the same time each day; using electronic data collection systems that prompt participants to complete their PROs; using verbal descriptors of symptoms, such as none, mild, moderate, severe; and limiting the number of items to be assessed to avoid subject burden.

When considering endpoints, the FDA says trials should be aware that different COVID-19 symptoms progress and resolve at different rates and that understanding of those timepoints is still evolving. Data from early-phase trials can be used to determine the effect of the investigational drug on the timing of symptoms, the guidance suggests.

The guidance also stresses the need to minimize missing data and offers such recommendations as providing reminders to participants, monitoring participants’ PRO completion, following up with those who are not completing their PROs and recording verbal responses of participants who are not able to complete reports. Informed consent documents should educate trial participants about the importance of providing follow-up data even if they leave the trial.

The guidance does not apply to trials of drugs to treat postinfectious conditions or development programs for preventive vaccines.

While the guidance is intended to remain in effect only for the duration of the current public health crisis, the FDA says it will revise and replace the document within 60 days of the end of the crisis based on public comments received and the agency’s experience in implementing the guidance.

To read the final guidance, click here: https://bit.ly/3ktQFhr.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing